SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Fundrise Innovation Fund LLC. - Common Shares of Limited Liability Company Interests

Fundrise Innovation Fund 

VCX is trending as retail traders scramble for exposure to AI leaders like OpenAI, Anthropic, and SpaceX, fueling a meme-like frenzy that has sent the stock soaring despite warnings of extreme overvaluation relative to its net asset value. Community members are actively debating the sustainability of this parabolic run, with many highlighting that the limited tradable float due to lockup periods is creating intense volatility and aggressive short-squeeze dynamics.

Far below the surface, where light no longer reaches and noise collapses into silence, the Sperm Whale endures.  It does not rely on speed or spectacle. It survives through mass, intelligence, and absolute awareness of its surroundings.  This project is shaped by the same principle — strength formed under pressure, movement guided by understanding, and conviction built where others cannot remain.  While the surface reacts, the deep decides.

The Sperm Whale

Sperm Whale is currently trending as a highly speculative meme coin on Solana, driving intense debate between participants chasing rapid, high-percentage gains and skeptics warning of potential pump-and-dump mechanics. Community sentiment is deeply polarized, with some bullish traders highlighting the project's chart structure and whale-driven price action, while others caution that the lack of fundamental utility and high concentration among top holders signal a significant risk.

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-ß agonist, and a preclinical GLP-1 receptor agonist program. The company was founded by Randall L. Halcomb, Martijn Fenaux, and Weidong Zhong in 2017 and is headquartered in Foster City, CA.

Terns Pharmaceuticals Inc

Terns Pharmaceuticals is capturing significant investor attention following promising Phase 1 clinical data for its leukemia candidate, TERN-701, which has sparked intense debate over the company's valuation and potential as an acquisition target. The community is deeply divided between bulls citing the drug's best-in-disease profile and analysts raising price targets, while bears express skepticism about the sustainability of the current valuation and the potential for near-term dilutive share offerings.

Destiny Tech100, Inc. operates as a non-diversified, closed-end management investment company. The company was founded on November 18, 2020 and is headquartered in Austin, TX.

Destiny Tech100 Inc

DESTINY TECH 100 INC

Destiny Tech 100 is capturing significant retail interest driven by its concentrated exposure to private tech leaders like SpaceX and Anthropic, which investors are tracking closely ahead of potential IPO activity. The community is actively debating the stock's substantial premium to its net asset value, with traders comparing its valuation mechanics to other proxy investment funds in the sector.

Circle Internet Group, Inc. is a financial technology company that enables businesses of all sizes to harness the power of digital currencies and public blockchains for payments, commerce and financial applications worldwide. The company was founded by Jeremy J. Allaire and Patrick Sean Neville in August 2013 and is headquartered in New York, NY.

Circle Internet Group Inc. - Ordinary Shares - Class A

Circle

Circle ($CRCL) is experiencing significant volatility following a leaked draft of the Clarity Act, which proposes banning stablecoin yield-sharing models and has sparked intense debate over the long-term viability of the company's revenue model. While some retail investors are buying the dip and betting on Circles role as a future payment utility, others remain skeptical, pointing to aggressive insider selling and ongoing regulatory uncertainty as signs of an overvalued asset.

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor Technologies is trending as investors debate whether the company's AI-driven platform and mortgage innovation represent a high-growth turnaround or a business model inherently vulnerable to high mortgage rates and macroeconomic pressures. The community remains intensely polarized, with bulls highlighting the firms increasing acquisition volume and leadership strategy, while bears continue to focus on the company's profitability challenges and its sensitivity to broader market volatility.

Personalis, Inc. engages in the provision of advanced genomic tests for cancer. The firm is also involved in providing sequencing and data analysis services to support population sequencing initiatives. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in February 2011 and is headquartered in Fremont, CA.

Personalis Inc

Personalis is trending as investors focus on recent positive updates regarding Medicare coverage prospects and the company's strong clinical test volume growth, which is being driven by its pivotal role in the precision oncology ecosystem alongside Tempus. The community is actively debating the company's long-term potential as a 'picks and shovels' leader in cancer diagnostics, closely monitoring upcoming earnings and the timing of regulatory milestones that could trigger a significant re-rating of the stock.

Axon Enterprise, Inc. engages in the development, manufacture, and sale of conducted electrical weapons for personal defense. It operates through the TASER segment and Software and Sensors segment. The TASER segment sells conducted electrical weapons, accessories, and other related products and services. The Software and Sensors segment includes devices, wearables, applications, cloud, and mobile products. The company was founded by Patrick W. Smith and Thomas P. Smith on September 7, 1993 and is headquartered in Scottsdale, AZ.

Axon Enterprise Inc

Axon Enterprise is trending as the stock undergoes significant volatility and a sharp multi-day decline, sparking intense debate among retail traders regarding the cause of the selloff. The community is actively discussing the stock's high valuation, frequent insider selling, and potential institutional manipulation, while many long-term shareholders remain focused on the company's dominant market position and growth outlook in the public safety sector.

AleAnna, Inc. operates as a technology-driven energy company, which engages in supplying low-carbon natural gas and renewable natural gas to Italy. The company was founded in 2007 and is headquartered in Dallas, TX.

AleAnna Inc. - Ordinary Shares - Class A

ANNA is currently trending as investors weigh conflicting reports regarding potential de-escalation in the Middle East against the long-term supply constraints caused by damage to critical energy infrastructure. Community discussion remains heavily focused on the stock's volatility, high cost-to-borrow rates, and its potential as a momentum play while traders analyze whether recent market movements are driven by genuine diplomatic progress or political market manipulation.

FuboTV, Inc. is a consumer-first live TV streaming company with the mission of delivering premium sports, news and entertainment programming that offers greater choice, flexibility and value. The company was founded by David Gandler, Alberto Horihuela Suarez, and Sung Ho Choi on February 20, 2009 and is headquartered in New York, NY.

fuboTV Inc - Ordinary Shares - Class A

fuboTV Inc

FuboTV investors are currently fixated on the company's approved 1-for-12 reverse stock split, which has sparked intense debate regarding potential dilution and the stock's long-term valuation. Community sentiment is deeply polarized between long-term holders frustrated by management's silence and the lack of major sports content, and speculative traders looking for volatility catalysts amidst low liquidity.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Biotech-focused investor Cormorant Asset Management rebuilt its stake above 6% on Tuesday.</li><li>Cormorant disclosed ownership of 4.36 million shares, up from about 2 million shares in October.</li><li>Retail sentiment flipped to ‘extremely bullish’ from ‘extremely bearish’ on Stocktwits, and message volume surged more than 900%.</li></ul>Shares of MoonLake Immunotherapeutics, Inc. jumped 11% on Tuesday, marking the stock’s biggest rally in over a month, after a biotech-focused investment firm rebuilt its stake amid heightened buzz among retail traders speculating a possible takeover.<h2 class="st-heading-2">Cormorant Lifts MoonLake Stake Above 6%</h2>A Schedule 13G filing on Tuesday showed Cormorant Asset Management reported ownership of 4.36 million Class A ordinary shares in MoonLake Immunotherapeutics, representing a 6.1% stake as of Dec. 31, 2025. The stake increased from about 2 million shares, or 3.14%, disclosed in October 2025 filings, after the firm had previously reduced its position below the 5% reporting threshold.Cormorant Asset Management is a biotech-specialised investment management firm with stakes in Praxis Precision Medicines, BridgeBio Oncology Therapeutics, Edgewise Therapeutics, and Metsera, which was acquired last year by Pfizer, among others.According to data from Quiver Quantitative, the firm reported holdings in 43 stocks as of Sept. 30, 2025, with an estimated portfolio value of about $1.45 billion.<h2 class="st-heading-2">FDA Momentum Builds Around Sonelokimab</h2>Earlier this month, the U.S. Food and Drug Administration (FDA) granted Fast Track designation to the company’s lead investigational therapy, Sonelokimab, for moderate-to-severe palmoplantar pustulosis. The company plans to pursue a biologics license application for Sonelokimab in hidradenitis suppurativa in the second half of 2026.Last month, MoonLake said a Type B meeting with the FDA confirmed its clinical evidence strategy for Sonelokimab in hidradenitis suppurativa. Following that update, several brokerages raised price targets or upgraded the stock, though&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/mltx-stock-erases-most-of-2025-loses-wall-street-retail-bets-on-fda-feedback-for-sonelokima/cmU1QhGR471">Goldman Sachs</a> downgraded MoonLake to ‘Sell’ last month, citing “high risk” around approvability in hidradenitis suppurativa.The company is scheduled to host an investor day on Feb. 23, at which it plans to provide updates on the clinical development and regulatory pathway for Sonelokimab across multiple inflammatory disease indications.<h2 class="st-heading-2">Stocktwits Buzz Erupts Around MLTX</h2>On Stocktwits, retail sentiment for MLTX flipped to ‘extremely bullish’ from ‘extremely bearish’ over the past day amid over a 900% surge in 24-hour message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/mltx_ss_png_b0740594f9.webp" alt="mltx ss.png" width="971" height="140"><figcaption>MLTX sentiment and message volume as of February 17 | Source: Stocktwits</figcaption></figure>One user said the Cormorant filing has “fundamentally broken” the short thesis. “Cormorant—who knows the science better than anyone—just admitted the "Bear Thesis" was wrong by buying back in at $12-$16.”<stembedurl>https://stocktwits.com/septrading/message/645184471</stembedurl>Another user said, “I can’t stop thinking that we get a PR of some sort, even a little teaser, PM tomorrow AM” ahead of the company’s investor day.<stembedurl>https://stocktwits.com/BOOPIE2020/message/645177386</stembedurl>A third user said, “I have to say that something may be coming..This price action today was solid coupled with the high after hours volume. Someone is accumulating.”<stembedurl>https://stocktwits.com/TDMF123/message/645174457</stembedurl>A separate user said they were watching for either a buyout announcement or positive regulatory news this week, while another argued MoonLake would need to trade higher before attracting interest from a large pharmaceutical acquirer.<stembedurl>https://stocktwits.com/Warren_8/message/645090086</stembedurl><stembedurl>https://stocktwits.com/Newcar/message/645134185</stembedurl>One user pointed to recent travel activity involving Merck’s corporate jet, hinting at a potential takeover by the big pharma firm and noted multiple trips to Zurich, where MoonLake is headquartered.&nbsp;<stembedurl>https://stocktwits.com/Bigpapa46/message/645006814</stembedurl>MLTX stock has risen 33% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a MoonLake Immunotherapeutics company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

MoonLake Stock Soars As Biotech Fund Reloads, Takeover Chatter Ignites

Optimism also grew around FDA momentum for its palmoplantar pustulosis drug ahead of MoonLake’s Feb. 23 investor day.

Equity

Promising Mid Cap Stocks Worth Watching - November 20th

Direxion Daily TSLA Bull 2X Shares, Metsera, and AltC Acquisition are the three Mid Cap stocks to watch today, according to MarketBeat's stock screener tool. Mid-cap stocks are shares of companies...

Best Pharmaceutical Stocks To Follow Today - November 20th

Metsera, Eli Lilly and Company, and Regeneron Pharmaceuticals are the three Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of...

Best Medical Stocks To Keep An Eye On - November 20th

Exact Sciences, Metsera, Eli Lilly and Company, UnitedHealth Group, Regeneron Pharmaceuticals, Johnson & Johnson, and Abbott Laboratories are the seven Medical stocks to watch today, according to...

Top Mid Cap Stocks To Follow Now - November 19th

Light & Wonder, ProShares UltraPro Short QQQ, Metsera, Direxion Daily TSLA Bull 2X Shares, and AltC Acquisition are the five Mid Cap stocks to watch today, according to MarketBeat's stock screener...

Best Pharmaceutical Stocks To Follow Today - November 19th

Metsera, Eli Lilly and Company, Pfizer, AbbVie, Regeneron Pharmaceuticals, Novo Nordisk A/S, and AstraZeneca are the seven Pharmaceutical stocks to watch today, according to MarketBeat's stock...

Best Medical Stocks To Watch Now - November 19th

Metsera, Eli Lilly and Company, UnitedHealth Group, Johnson & Johnson, and Boston Scientific are the five Medical stocks to watch today, according to MarketBeat's stock screener tool. Medical stocks...

Best Value Stocks To Follow Now - November 19th

Invesco QQQ, ProShares UltraPro Short QQQ, Metsera, Boeing, Circle Internet Group, Nebius Group, and CoreWeave are the seven Value stocks to watch today, according to MarketBeat's stock screener...

Mid Cap Stocks To Research - November 18th

ProShares UltraPro Short QQQ, Light & Wonder, Metsera, Direxion Daily TSLA Bull 2X Shares, Ondas, AltC Acquisition, and Rigetti Computing are the seven Mid Cap stocks to watch today, according to...

Top Medical Stocks Worth Watching - November 18th

Metsera, UnitedHealth Group, Eli Lilly and Company, Merck & Co., Inc., and Olema Pharmaceuticals are the five Medical stocks to watch today, according to MarketBeat's stock screener tool. Medical...

Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell on June 29, 2022 and is headquartered in New York, NY.

MTSR
Metsera Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MTSR News

MTSRMetsera Inc